Compare NUVL & COLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NUVL | COLB |
|---|---|---|
| Founded | 2017 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 8.5B |
| IPO Year | 2021 | N/A |
| Metric | NUVL | COLB |
|---|---|---|
| Price | $100.82 | $31.45 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 14 |
| Target Price | ★ $135.00 | $31.18 |
| AVG Volume (30 Days) | 497.6K | ★ 3.1M |
| Earning Date | 02-27-2026 | 01-22-2026 |
| Dividend Yield | N/A | ★ 4.74% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.30 |
| Revenue | N/A | ★ $2,151,000,000.00 |
| Revenue This Year | N/A | $32.03 |
| Revenue Next Year | N/A | $2.85 |
| P/E Ratio | ★ N/A | $13.59 |
| Revenue Growth | N/A | ★ 17.96 |
| 52 Week Low | $55.54 | $19.61 |
| 52 Week High | $113.02 | $32.70 |
| Indicator | NUVL | COLB |
|---|---|---|
| Relative Strength Index (RSI) | 49.64 | 58.14 |
| Support Level | $98.65 | $30.75 |
| Resistance Level | $106.57 | $32.62 |
| Average True Range (ATR) | 4.46 | 0.84 |
| MACD | -0.29 | 0.09 |
| Stochastic Oscillator | 47.36 | 57.73 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Columbia Banking System Inc is a registered bank holding company whose wholly-owned banking subsidiary is Columbia State Bank. The company provides a full range of banking services to small and medium sized businesses, professionals, and individuals throughout Washington, Oregon, Idaho, and California. The company's subsidiary Columbia Trust Company is an Oregon trust company that provides agency, fiduciary, and other related trust services with offices in Washington, Oregon, and Idaho. The firm offers various products and services under Personal Banking, Business Banking, and Wealth Management divisions.